RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
Research output: Contribution to journal › Journal article › Research › peer-review
To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischaemic events in acute coronary syndrome (ACS).
| Original language | English |
|---|---|
| Journal | European Heart Journal (Online) |
| Volume | 32 |
| Issue number | 20 |
| Pages (from-to) | 2541-54 |
| Number of pages | 14 |
| ISSN | 1522-9645 |
| DOIs | |
| Publication status | Published - Oct 2011 |
ID: 48592247